IRX2-DT
Putative uncharacterized protein IRX2-DT
Also known as: CEI_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for IRX2-DT in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
138 residues, UniProt reviewed canonical sequence.
>Q86SI9|IRX2-DT
1 MVAPAARVFL RAVRAALTST VPDLLCLLAR GSPRGLASGR LPLAVHSAQH GPGSGAPWLR
61 IARRALRFVL SKHWGDDCYL TNRLWQDLKP PSHVENGQEL RLAPPVQWAL QVQGNQLQTA
121 VLCLRMAPPE PAGSRQRILocalizationUniProt · AlphaFold · HPA
Whether an antibody against IRX2-DT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.59
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IRX2-DT as an antibody target. Whether an autoantibody or antibody against IRX2-DT could matter depends on whether native IRX2-DT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IRX2-DT is annotated as secreted, so native IRX2-DT circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IRX2-DT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...